VANGUARD GROUP INC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 162 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2013. The put-call ratio across all filers is 0.83 and the average weighting 0.3%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2018$1,239,000
-54.6%
6,261,903
+3.5%
0.00%
Q3 2018$2,728,000
-3.7%
6,047,564
+7.5%
0.00%
Q2 2018$2,833,000
-79.8%
5,625,864
-6.4%
0.00%
-100.0%
Q1 2018$13,999,000
-42.3%
6,007,985
-29.6%
0.00%0.0%
Q4 2017$24,248,000
+10.5%
8,538,175
+11.3%
0.00%0.0%
Q3 2017$21,941,000
-9.1%
7,671,589
-21.5%
0.00%0.0%
Q2 2017$24,143,000
-26.2%
9,774,858
+7.8%
0.00%
-50.0%
Q1 2017$32,731,000
+18.7%
9,066,763
+16.4%
0.00%0.0%
Q4 2016$27,571,000
-8.9%
7,788,557
+4.0%
0.00%0.0%
Q3 2016$30,252,000
-5.1%
7,487,884
+3.1%
0.00%0.0%
Q2 2016$31,886,000
+24.6%
7,263,339
+7.3%
0.00%0.0%
Q1 2016$25,595,000
-76.0%
6,771,237
-0.3%
0.00%
-71.4%
Q4 2015$106,488,000
-77.4%
6,791,275
-69.3%
0.01%
-61.1%
Q3 2015$470,584,000
+193.4%
22,140,820
+248.2%
0.02%
+63.6%
Q2 2015$160,368,000
-5.5%
6,358,746
+4.4%
0.01%
-8.3%
Q1 2015$169,744,000
+72.1%
6,090,594
+12.7%
0.01%
+71.4%
Q4 2014$98,648,000
+46.3%
5,405,353
+3.9%
0.01%
+40.0%
Q3 2014$67,417,000
-20.2%
5,201,935
+0.4%
0.01%
-28.6%
Q2 2014$84,531,000
-5.9%
5,179,569
+1.9%
0.01%
-12.5%
Q1 2014$89,818,000
-25.4%
5,083,094
+2.2%
0.01%
-27.3%
Q4 2013$120,379,000
-11.0%
4,972,275
+30.2%
0.01%
-15.4%
Q3 2013$135,318,000
+244.3%
3,819,298
+51.7%
0.01%
+225.0%
Q2 2013$39,304,0002,517,9060.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q4 2013
NameSharesValueWeighting ↓
TSP Capital Management Group, LLC 813,273$3,286,0001.66%
RTW INVESTMENTS, LP 1,243,164$5,022,0001.52%
Marcus Capital, LLC 112,200$453,0000.44%
BOGLE INVESTMENT MANAGEMENT L P /DE/ 996,178$4,024,0000.29%
Benchmark Capital Advisors 67,000$271,0000.20%
SUFFOLK CAPITAL MANAGEMENT LLC 360,299$1,456,0000.20%
COLUMBIA WANGER ASSET MANAGEMENT LLC 2,907,523$11,746,0000.15%
Virtus ETF Advisers LLC 59,537$241,0000.12%
Bellevue Group AG 160,000$646,0000.12%
PDT Partners, LLC 428,300$1,730,0000.10%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders